The Drug Shortage Crisis in the United States: Impact on Cancer Pharmaceutical Safety
- 15 December 2018
- book chapter
- Published by Springer Nature
- Vol. 171, 75-92
Abstract
Drug shortages pose a significant public health concern in the United States, and cancer drugs are among those most affected. Shortages present serious safety risks for patients and substantial burden on providers and the healthcare system. Multifaceted drivers of this complex problem include manufacturing disruptions, raw material shortages, regulatory issues, market dynamics, and limited financial incentives that reward quality and production of off-patent drugs. Oncology drugs in short supply have resulted in substitution of less effective or more toxic alternatives, medication errors, and treatment delays, and are especially concerning for medications with no adequate substitute. Consequently, patient outcomes such as disease progression and survival have been adversely affected. Furthermore, emerging gray markets have contributed to cost-prohibitive markups and introduction of counterfeit products that compromise patient safety. The Food and Drug Administration plays a key role in preventing and managing pharmaceutical shortages, largely through regulations requiring early notification of manufacturing interruptions. Other proposed strategies similarly target upstream causes and center on reducing regulatory hurdles for manufacturers and increasing incentives for market entry and quality improvement. Despite progress in preventing supply disruptions, continued exploration of underlying systemic drivers remains critical to informing long-term solutions and alleviating the clinical and economic impact of drug shortages.Keywords
This publication has 37 references indexed in Scilit:
- Oncology and the Internet: Regulatory Failure and ReformJournal of Oncology Practice, 2012
- Drug Shortages — A Critical Challenge for the Generic-Drug MarketNew England Journal of Medicine, 2011
- The Shortage of Essential Chemotherapy Drugs in the United StatesNew England Journal of Medicine, 2011
- Efforts Underway To Curb Drug ShortagesJNCI: Journal of the National Cancer Institute, 2011
- The Reality of Drug Shortages — The Case of the Injectable Agent PropofolNew England Journal of Medicine, 2010
- Cost Effectiveness of Evidence-Based Treatment Guidelines for the Treatment of Non–Small-Cell Lung Cancer in the Community SettingJournal of Oncology Practice, 2010
- ASHP Guidelines on Managing Drug Product Shortages in Hospitals and Health SystemsAmerican Journal of Health-System Pharmacy, 2009
- Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- Prevalence of Outpatient Cancer Treatment in the United States: Estimates from the Medical Panel Expenditures Survey (MEPS)Cancer Investigation, 2008
- Does Reimbursement Influence Chemotherapy Treatment For Cancer Patients?Health Affairs, 2006